Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

Christian Glennie

Edison Investment Research

Image: Christian Glennie

Christian Glennie joined the healthcare team at Edison Investment Research in January 2012 and has 11 years' experience covering the global biotech/pharmaceutical sector as an analyst and a journalist. He came to Edison having held senior analyst and editorial roles at EvaluatePharma and EP Vantage. Christian Glennie also has prior experience as a marketing analyst at Zeneca Agrochemicals.




Recent Interviews

Seven Biotech Options that Buck Tradition: Christian Glennie (6/6/13) Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. What's unusual is that Edison looks for tomorrow's upside in companies still small enough to double, triple and quadruple in value down the line. In this interview with The Life Sciences Report, Edison Biotechnology Analyst Christian Glennie applies his valuation skills to seven innovative biotech and specialty pharma companies and discusses the share-moving catalysts that investors need to know about now.

Recent Quotes

"Positive Phase 2 data in ischemic stroke could significantly rerate ATHX stock." (3/5/15) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"We estimate ATHX's MultiStem to hit peak sales of $3B across the US, EU and Japan." (1/12/15) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"ATHX is well positioned in terms of its stage of development and the profile of its MAPCs." (11/24/14) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"Positive Phase 2 data in ischemic stroke could rerate ATHX's stock." (9/24/14) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"ATHX's Phase 2, ischemic stroke study results are expected in Q4/14." (6/30/14) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"Potential FDA clearance for VRS' Aura is a key near-term catalyst." (6/30/14) Verisante Technology Inc. - Christian Glennie, Edison Investment Research Moreá>

"A key, near-term catalyst for VRS is 501(k) FDA clearance for Aura." (6/2/14) Verisante Technology Inc. - Christian Glennie, Edison Investment Research Moreá>

"ATHX is well capitalized with $45M in cash at Q1/14E." (5/6/14) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

more comments

"ATHX's big cash balance will allow it to fully exploit MultiStem's undeniable potential." (1/21/14) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"Results in 2014 from ATHX's phase 2 studies could rerate the stock." (12/2/13) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"ATHX's encouraging phase 1 trials have demonstrated MultiStem's safety and efficacy." (10/25/13) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"A $2.8M research grant enables ATHX's MultiStem to enter a third phase 2 trial to evaluate the safety and therapeutic impact of its allogeneic adult stem cells." (8/9/13) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"ATHX showed MultiStem increases long term survival of organ transplants." (7/16/13) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"Positive results from ATHX's phase 2 MultiStem trial could catalyze the stock and lead to a lucrative licensing deal." (6/26/13) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie Moreá>

"ATHX has gained 25% in the last month; we see its enterprise value rising further." (5/7/13) Athersys Inc. - Christian Glennie, Edison Investment Research Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.